https://www.selleckchem.com/pr....oducts/2-aminoethane
5. Patients with M2BPGi ≥1.5 had a higher incidence of adverse events such as fatigue and anorexia. Baseline M2BPGi levels may predict the tolerability and treatment response to lenvatinib. Patients with high M2BPGi levels may less likely to benefit from lenvatinib therapy. Baseline M2BPGi levels may predict the tolerability and treatment response to lenvatinib. Patients with high M2BPGi levels may less likely to benefit from lenvatinib therapy. To evaluate the baseline clinical characteristics of juvenile systemic sclerosis
Like
Comment
Share
